Our new AI assistant can help patients, caregivers, and researchers find important information faster. Click the logo in the lower right corner to try it.
The Fibrolamellar Cancer Foundation has awarded a new research grant to Paul Thomas, PhD, of the Fred Hutchinson Cancer Center in Seattle, Washington to advance the development of T-cell receptor-engineered T-cell (TCR-T) therapies for fibrolamellar carcinoma (FLC). FLC is driven by the DNAJB1-PRKACA fusion protein, a unique cancer-specific target that is absent from healthy cells. …
For patients and families affected by fibrolamellar cancer (FLC), hope is built through progress. Every discovery, every research collaboration, and every clinical trial brings us closer to better treatments for this devastating disease. Today, that progress is becoming increasingly tangible. Researchers are translating laboratory discoveries into clinical trials that offer new treatment opportunities for people …
A clinical trial of a new combination immune therapy specifically designed for fibrolamellar carcinoma (FLC) is beginning at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University (Baltimore, MD). The study is led by Drs. Marina Baretti and Mark Yarchoan. Importantly, this trial builds directly on findings from earlier studies that demonstrated the promise …
The Fibrolamellar Cancer Foundation (FCF) has awarded a new research grant to investigators at the Icahn School of Medicine at Mount Sinai in New York City. Research has identified SLC16A14 as one of the most highly upregulated genes in FLC, making it a potential candidate for therapeutic development. However, much remains unknown about SLC16A14’s biological …
FCF is please to announce that it has awarded a new grant to Mark Yarchoan, MD, and Waqar Arif, MD, of Johns Hopkins University to identify actionable antibody-drug conjugate targets in FLC. Antibody-drug conjugates (ADCs) are an emerging class of targeted cancer therapies sometimes described as “smart chemotherapy.” They combine an antibody that recognizes a …
Registration is now open for the Patient & Family Gathering to be held on September 18 – 20, 2026, at the Lake Mansfield Trout Club in Stowe, Vermont. This unique event brings together patients, families and caregivers dealing with fibrolamellar, helping them build connections and friendships with others facing similar challenges. Please click here to …
Participation in clinical trials can be critical for fibrolamellar carcinoma patients—but the cost of travel, lodging, and time away from work or school can prevent many from enrolling. FCF is working to reduce these barriers with its Clinical Trial Patient Assistance Program, which provides housing assistance for patients with financial need while they are participating …
A recent article from the University of Wisconsin highlights ongoing progress in fibrolamellar carcinoma (FLC) research led by Dr. Sean Ronnekleiv-Kelly, a surgical oncologist focused on improving outcomes for this ultra-rare liver cancer. Dr. Ronnekleiv-Kelly’s work centers on understanding how these tumors develop and identifying potential treatment targets. His lab studies patient tumors and pre-clinical …
In a recent study funded by FCF, researchers at the University of Washington, Fred Hutchinson Cancer Center, and Cornell University shed important light on why immunotherapy has struggled to work in fibrolamellar carcinoma (FLC). Led by Dr. Venu G. Pillarisetty and Dr. Praveen Sethupathy, a collaborative, multidisciplinary team set out to understand why treatments like …